Elenbecestat

Catalog No.S8600 Synonyms: E2609

For research use only.

Elenbecestat (E2609) is a novel BACE1 inhibitor, demonstrating prolonged reductions in plasma beta-amyloid levels after single dosing.

Elenbecestat Chemical Structure

CAS No. 1388651-30-6

Purity & Quality Control

Choose Selective BACE Inhibitors

Biological Activity

Description Elenbecestat (E2609) is a novel BACE1 inhibitor, demonstrating prolonged reductions in plasma beta-amyloid levels after single dosing.

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 437.44
Formula

C19H18F3N5O2S

CAS No. 1388651-30-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1C2CSC(=NC2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(N=C4)C(F)F)F)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03055962 Completed Drug: E2609|Drug: Placebo Healthy Participants Eisai Co. Ltd.|Eisai Inc. February 14 2017 Phase 1
NCT02859207 Completed Drug: E2609 Early Alzheimer''s Disease Eisai Inc. August 2016 Phase 1
NCT02322021 Terminated Drug: E2609|Drug: Placebo Alzheimer Disease|Dementia Alzheimer Type Eisai Inc.|Biogen November 26 2014 Phase 2
NCT02222324 Completed Drug: Placebo|Drug: E2609|Drug: Moxifloxacin Healthy Subjects Eisai Inc. August 2014 Phase 1
NCT02207790 Completed Drug: E2609|Drug: Placebo Healthy Subjects Eisai Inc. July 2014 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Elenbecestat | Elenbecestat supplier | purchase Elenbecestat | Elenbecestat cost | Elenbecestat manufacturer | order Elenbecestat | Elenbecestat distributor